New drug combo trial offers hope for tough breast cancer
NCT ID NCT07487519
Summary
This study is testing whether a new drug called HLX43, either alone or combined with existing immunotherapies, can help control advanced triple-negative breast cancer. Researchers will enroll 180 adults whose cancer has spread or returned after treatment. The main goals are to see if the treatment shrinks tumors and how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.